Effect of duloxetine administration in patients with depressive symptoms undergoing total hip arthroplasty: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054655

Enrollment

Unknown

Registered

2021-12-23

Start date

2021-12-21

Completion date

Unknown

Last updated

2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group:Duloxetine

Control group:Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 to 85 years who need to undergo primary unilateral hip replacement; 2. 17-item Hamilton depression score more than 8 points.

Exclusion criteria

Exclusion criteria: 1. ASA classification level 4; 2. Duloxetine allergy; 3. History of related drug use (SNRI, SSRI or other antidepressant drugs) 6 months before surgery; 4. Liver and kidney function damage; 5. Coagulation disease; 6. Central or peripheral nerve injury; 7. Cognitive dysfunction; 8. Opioid or alcohol dependence.

Design outcomes

Primary

Measure	Time frame
Pain with ambulation;	—

Secondary

Measure	Time frame
Pain with hip flexion;Pain at rest;Hip range of motion;	—

Countries

China

Contacts

Public ContactZhou Zongke

West China Hospital, Sichuan University

zhouzongke@scu.edu.cn+86 18980601028

Outcome results